Tramadol extended release - Cipher Pharmaceuticals

Drug Profile

Tramadol extended release - Cipher Pharmaceuticals

Alternative Names: CIP-Tramadol ER; Conzip; Durela; Extended-release tramadol

Latest Information Update: 22 Feb 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cipher Pharmaceuticals
  • Class Antidepressants; Cyclohexanols; Dimethylamines; Erectile dysfunction therapies; Opioid analgesics; Phenyl ethers; Small molecules
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Pain

Most Recent Events

  • 08 Mar 2016 Biomarkers information updated
  • 17 Jun 2015 Tribute Pharmaceuticals Canada acquires Medical Futures
  • 29 Apr 2013 Tramadol extended-release licensed to Tecnofarma for commercialisation in Latin America
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top